Literature DB >> 27648366

Prognostic significance of MST1R dysregulation in renal cell tumors.

Ana S Pires-Luís1, Márcia Vieira-Coimbra1, Maria João Ferreira2, João Ramalho-Carvalho2, Pedro Costa-Pinheiro2, Luís Antunes3, Paula C Dias4, Francisco Lobo5, Jorge Oliveira5, Inês Graça2, Rui Henrique6, Carmen Jerónimo7.   

Abstract

Macrophage stimulating 1 receptor (MST1R) is a C-MET proto-oncogene family receptor tyrosine kinase. Promoter methylation patterns determine transcription of MST1R variants as hypermethylation of a region upstream of transcription start site (TSS) is associated with lack of MST1R long transcript (MST1R long) and expression of a short transcript with oncogenic potential. Thus, we aimed to investigate MST1R variant transcript regulation in renal cell tumors (RCT) and assess their prognostic potential. We found, in a series of 120 RCT comprising the four main subtypes (clear cell, papillary and chromophobe renal cell carcinoma, and oncocytoma), that higher methylation levels close to TSS were associated with total MST1R expression levels (MST1R total) in primary tumors (p=0.049) and renal cancer cell lines. After demethylating treatment, MST1R long/MST1R total ratio increased, as expected, in two renal cell carcinoma cell lines tested. However, in primary tumors with hypermethylation upstream of TSS, a decrease in MST1R long/MST1R total ratio was not detected, although higher expression ratio of nuclear factor-κB was apparent. Furthermore, survival analysis demonstrated that MST1R long/MST1R total ratio was independently associated with shorter disease-specific and disease-free survival, whereas MST1R total expression associated with shorter disease-specific survival. In conclusion, although promoter methylation patterns seem to determine MST1R global transcription regulation in renal cell carcinoma, other mechanisms might contribute to deregulate MST1R variant expression in RCT. Nevertheless, MST1R total expression and MST1R long/MST1R total ratio modulate the biological and clinical aggressiveness of renal cell carcinoma, as depicted by its prognostic significance, a finding that requires validation in a larger independent series.

Entities:  

Keywords:  MST1R; MST1R expression; MST1R promoter methylation; RON; Renal cell tumors; epigenetics

Year:  2016        PMID: 27648366      PMCID: PMC5004080     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  39 in total

1.  Involvement of recepteur d'origine nantais receptor tyrosine kinase in Epstein-Barr virus-associated nasopharyngeal carcinoma and its metastasis.

Authors:  Ya-Ching Chou; Chi-Long Chen; Te-Huei Yeh; Sue-Jane Lin; Mei-Ru Chen; Shin-Lian Doong; Jean Lu; Ching-Hwa Tsai
Journal:  Am J Pathol       Date:  2012-09-11       Impact factor: 4.307

2.  Identification of novel target genes by an epigenetic reactivation screen of renal cancer.

Authors:  Inmaculada Ibanez de Caceres; Essel Dulaimi; Amanda M Hoffman; Tahseen Al-Saleem; Robert G Uzzo; Paul Cairns
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

3.  The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

Authors:  Piera Maggiora; Annalisa Lorenzato; Stefano Fracchioli; Barbara Costa; Massimo Castagnaro; Riccardo Arisio; Dionyssios Katsaros; Marco Massobrio; Paolo M Comoglio; Maria Flavia Di Renzo
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

4.  Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3.

Authors:  T Yoshimura; N Yuhki; M H Wang; A Skeel; E J Leonard
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

5.  CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.

Authors:  Ichiro Kagara; Hideki Enokida; Kazumori Kawakami; Ryouichirou Matsuda; Kazuki Toki; Hiroaki Nishimura; Takeshi Chiyomaru; Shuichi Tatarano; Toshihiko Itesako; Ken Kawamoto; Kenryu Nishiyama; Naohiko Seki; Masayuki Nakagawa
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

6.  Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.

Authors:  M R Morris; C Ricketts; D Gentle; M Abdulrahman; N Clarke; M Brown; T Kishida; M Yao; F Latif; E R Maher
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

7.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

8.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.

Authors:  G Gaudino; A Follenzi; L Naldini; C Collesi; M Santoro; K A Gallo; P J Godowski; P M Comoglio
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

Review 9.  Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.

Authors:  Ming-Hai Wang; Ruiwen Zhang; Yong-Qing Zhou; Hang-Ping Yao
Journal:  J Biomed Res       Date:  2013-07-30

10.  Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.

Authors:  Patrícia Patrício; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Mafalda Almeida; João Diogo Barros-Silva; Joana Vieira; Paula Cristina Dias; Francisco Lobo; Jorge Oliveira; Manuel R Teixeira; Rui Henrique; Carmen Jeronimo
Journal:  J Cell Mol Med       Date:  2013-07-26       Impact factor: 5.310

View more
  2 in total

1.  Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel.

Authors:  Ana Sílvia Pires-Luís; Pedro Costa-Pinheiro; Maria João Ferreira; Luís Antunes; Francisco Lobo; Jorge Oliveira; Rui Henrique; Carmen Jerónimo
Journal:  J Transl Med       Date:  2017-06-29       Impact factor: 5.531

2.  A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.

Authors:  Rui Henrique; Carmen Jerónimo; João Ramalho-Carvalho; Céline S Gonçalves; Inês Graça; David Bidarra; Eva Pereira-Silva; Sofia Salta; Maria Inês Godinho; Antonio Gomez; Manel Esteller; Bruno M Costa
Journal:  Clin Epigenetics       Date:  2018-03-27       Impact factor: 6.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.